Journal
VACCINE
Volume 28, Issue 32, Pages 5315-5322Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.05.045
Keywords
Intradermal; Vaccine; Ricin
Categories
Funding
- NIH [AI-056372, 5T32GM008203]
Ask authors/readers for more resources
Ricin toxin is a CDC level B biothreat. We have developed a ricin vaccine, RiVax, which is a recombinant mutant of ricin A chain. RiVax is safe, immunogenic and protective in mice when administered intramuscularly (IM). We have now attempted to increase the utility and immunogenicity of RiVax by administering it intradermally (ID) with or without alum. Without alum, Rivax administered by the ID and IM routes was equally immunogenic and protective. With alum, ID vaccinations were more immunogenic and protective against both systemic and mucosal challenge with ricin and superior in protecting animals from ricin-induced lung damage. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available